From GlobeNewswire: 2025-04-21 23:37:00

AP Biosciences will present preclinical data on AP402, a groundbreaking bispecific antibody, at the AACR Annual Meeting in Chicago. The poster will highlight the potential of AP402 in targeting CD137 and p95HER2, with promising results in in-vivo and in vitro studies. This innovative antibody recently received IND clearance for clinical trials in Australia. Dr. Po-Lin Huang will present the poster on April 29, showcasing AP402’s potent antitumor activity. The design of AP402 aims to address treatment-resistant HER2-positive cancers, offering new hope for patients with refractory/recurrent tumors. AP Biosciences is at the forefront of developing cutting-edge antibody-based therapies for cancer and other diseases, utilizing their Omni-Mab and T-cube platforms to create next-generation bispecific antibodies that activate the immune system precisely where needed.



Read more at GlobeNewswire: UPDATE — AP Biosciences to Present New Preclinical Data at